An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

NCT03167437 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

35

Enrollment

NIH

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Vorinostat
DRUG: Ustekinumab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)